BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22667760)

  • 1. Polo-like kinases in AML.
    Berg T; Bug G; Ottmann OG; Strebhardt K
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
    Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
    Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
    Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
    Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
    Didier C; Cavelier C; Quaranta M; Demur C; Ducommun B
    Eur J Pharmacol; 2008 Sep; 591(1-3):102-5. PubMed ID: 18616938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
    Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting polo-like kinase 1 for cancer therapy.
    Strebhardt K; Ullrich A
    Nat Rev Cancer; 2006 Apr; 6(4):321-30. PubMed ID: 16557283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
    Chopra P; Sethi G; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions.
    Bahassi el M
    Exp Biol Med (Maywood); 2011 Jun; 236(6):648-57. PubMed ID: 21558091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo and Aurora kinases: lessons derived from chemical biology.
    Taylor S; Peters JM
    Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.